PharmaCyte Biotech Receives Noncompliance Notice From Nasdaq; Has Until June 2026 To Regain Compliance
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
PharmaCyte Biotech shares are trading higher after the company announced monetization of its stake in Femasys.
PharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M
PharmaCyte Biotech Q1 EPS $(1.23) Down From $1.90 YoY
PharmaCyte Biotech Invests Additional $3M In TNF Pharmaceuticals To Support LightSolver Partnership
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
PharmaCyte Biotech Q4 EPS $1.54 Up From $(0.33) YoY
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
PharmaCyte Biotech announces $7 million strategic investment in MYMD
MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
